Family history is significantly associated with prostate cancer and its early onset in Chinese population

Xu, Yu; Huang, Da; Wu, Yishuo; Ye, Dingwei; Zhang, Ning; Gao, Yi; Xu, Danfeng; Na, Rong; Xu, Jianfeng

doi:10.1002/pros.23900

Cited by 6 publications

(6 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly to already recognised and currently extensively discussed epidemic developments of other noncommunicable diseases such as type 2 diabetes [15] and breast cancer [16,17], the PCa management paradigm obviously requires a fundamental revision meeting needs of young populations [18], individuals at risk by both genetic and modifiable factors [19,20] as well as stratified patient cohorts benefiting from individualised treatment algorithms [21]. The article summarises knowledge accumulated in regard to the PCa-relevant non-modifiable and modifiable risk factors, highlights current deficits in PCa managements and presents innovative solutions in the context of predictive, preventive and personalised (3P) medicine (see Fig.…”

Section: Introductionmentioning

confidence: 99%

Prostate cancer management: long-term beliefs, epidemic developments in the early twenty-first century and 3PM dimensional solutions

Kučera¹,

Pecen²,

Topolčan³

et al. 2020

EPMA Journal

View full text Add to dashboard Cite

In the early twenty-first century, societies around the world are facing the paradoxal epidemic development of PCa as a non-communicable disease. PCa is the most frequently diagnosed cancer for men in several countries such as the USA. Permanently improving diagnostics and treatments in the PCa management causes an impressive divergence between, on one hand, permanently increasing numbers of diagnosed PCa cases and, on the other hand, stable or even slightly decreasing mortality rates. Still, aspects listed below are waiting for innovate solutions in the context of predictive approaches, targeted prevention and personalisation of medical care (PPPM / 3PM). PCa belongs to the cancer types with the highest incidence worldwide. Corresponding economic burden is enormous. Moreover, the costs of treating PCa are currently increasing more quickly than those of any other cancer. Implementing individualised patient profiles and adapted treatment algorithms would make currently too heterogeneous landscape of PCa treatment costs more transparent providing clear “road map” for the cost saving. PCa is a systemic multi-factorial disease. Consequently, predictive diagnostics by liquid biopsy analysis is instrumental for the disease prediction, targeted prevention and curative treatments at early stages. The incidence of metastasising PCa is rapidly increasing particularly in younger populations. Exemplified by trends observed in the USA, prognosis is that the annual burden will increase by over 40% in 2025. To this end, one of the evident deficits is the reactive character of medical services currently provided to populations. Innovative screening programmes might be useful to identify persons in suboptimal health conditions before the clinical onset of metastasising PCa. Strong predisposition to systemic hypoxic conditions and ischemic lesions (e.g. characteristic for individuals with Flammer syndrome phenotype) and low-grade inflammation might be indicative for specific phenotyping and genotyping in metastasising PCa screening and disease management. Predictive liquid biopsy tests for CTC enumeration and their molecular characterisation are considered to be useful for secondary prevention of metastatic disease in PCa patients. Particular rapidly increasing PCa incidence rates are characteristic for adolescents and young adults aged 15–40 years. Patients with early onset prostate cancer pose unique challenges; multi-factorial risks for these trends are proposed. Consequently, multi-level diagnostics including phenotyping and multi-omics are considered to be the most appropriate tool for the risk assessment, prediction and prognosis. Accumulating evidence suggests that early onset prostate cancer is a distinct phenotype from both aetiological and clinical perspectives deserving particular attention from view point of 3P medical approaches.

show abstract

Section: Introductionmentioning

confidence: 99%

Prostate cancer management: long-term beliefs, epidemic developments in the early twenty-first century and 3PM dimensional solutions

Kučera¹,

Pecen²,

Topolčan³

et al. 2020

EPMA Journal

View full text Add to dashboard Cite

show abstract

“…For example, a positive FH of prostate cancer (PCa) or BRCA‐related cancers was related to an earlier age at onset of PCa. 21 Besides, FH of colorectal cancer (CRC) was also considered to be associated with early-onset CRC (age <50 years). 22 The unusual discovery in this study of RCC has not been reported in any other epidemiological research, to our knowledge.…”

Section: Discussionmentioning

confidence: 99%

Family History of Cancers Increases Risk of Renal Cell Carcinoma in a Chinese Population

Xing¹,

Ruan²,

Huang³

et al. 2022

CMAR

Self Cite

View full text Add to dashboard Cite

Purpose To explore the impact of family history (FH) on renal cell carcinoma (RCC) and its pathological subtype clear cell RCC (ccRCC) in a Chinese population; a significant association has previously been determined not only in familial cancer syndrome but also in sporadic cases in western populations. Methods Consecutive patients with kidney tumors from October 2017 to May 2021 at a tertiary hospital in Shanghai were enrolled in the study. Demographic and clinical information was collected, including age, gender, FH (positive or negative, types of cancers, degree of relatives, etc.), pathological diagnosis, and Fuhrman grades. Results A positive FH of any cancer was observed in 26.5% of the RCC patients, while only 16.8% patients with benign kidney tumor were found to have a positive FH. A strong correlation was observed between FH of any cancers in first-degree relatives and RCC (odds ratio [OR]=4.60, 95% confidence interval [CI]: 1.95–10.85, P =5.50×10 −5 ) or ccRCC (OR=4.63, 95% CI: 1.95–11.02, P =9.63×10 −5 ). In subgroup analysis, FH of digestive cancers was significantly associated with RCC (OR=4.42, 95% CI: 1.35–14.51, P =0.005) or ccRCC (OR=4.14, 95% CI: 1.25–13.75, P =6.84×10 −4 ). Similar results were found in multivariate analyses. However, no significant association was observed between FH and age at onset. Conclusion FH was an independent risk factor for RCC and ccRCC in this Chinese population. FH of any cancer in first-degree relatives and FH of digestive cancers were found to be the most significant risk factors for kidney cancers.

show abstract

“…Reports revealed that the United States is expected to spend more than US$8 billion annually on the screening and treatment of PCA 2 . Incidence of PCA in China is lower than in the United States; however, in the past two decades, numbers of PCA patients have increased significantly due to environmental pollution, westernized change in diet, and aging of the population 3 . The prostate-specific antigen (PSA) is currently recognized as a useful tool for early screening of PCA 4 .…”

Section: Introductionmentioning

confidence: 93%

“…Compared to PPARG1, PPARG2 contains 30 additional amino acids at the N terminus and the ligand-independent activation activity is 5–10 times than that of PPARG1 12 . It has been reported that PPARG plays a role in a variety of chronic diseases including tumors 3 , 13 , diabetes 14 , inflammation 15 , atherosclerosis 16 , and so on. As far as PPARG2 is concerned, its role in PCA has not been clarified.…”

Section: Introductionmentioning

confidence: 99%

Upregulated PPARG2 facilitates interaction with demethylated AKAP12 gene promoter and suppresses proliferation in prostate cancer

Lü

Liu

et al. 2021

Cell Death Dis

View full text Add to dashboard Cite

Prostate cancer (PCA) is one of the most common male genitourinary tumors. However, the molecular mechanisms involved in the occurrence and progression of PCA have not been fully clarified. The present study aimed to investigate the biological function and molecular mechanism of the nuclear receptor peroxisome proliferator-activated receptor gamma 2 (PPARG2) in PCA. Our results revealed that PPARG2 was downregulated in PCA, and overexpression of PPARG2 inhibited cell migration, colony formation, invasion and induced cell cycle arrest of PCA cells in vitro. In addition, PPARG2 overexpression modulated the activation of the Akt signaling pathway, as well as inhibited tumor growth in vivo. Moreover, mechanistic analysis revealed that PPARG2 overexpression induced increased expression level of miR-200b-3p, which targeted 3′ UTR of the downstream targets DNMT3A/3B, and facilitated interaction with demethylated AKAP12 gene promoter and suppressed cell proliferation in PCA. Our findings provided the first evidence for a novel PPARG2-AKAP12 axis mediated epigenetic regulatory network. The study identified a molecular mechanism involving an epigenetic modification that could be possibly targeted as an antitumoral strategy against prostate cancer.

show abstract

Family history is significantly associated with prostate cancer and its early onset in Chinese population

Cited by 6 publications

References 13 publications

Prostate cancer management: long-term beliefs, epidemic developments in the early twenty-first century and 3PM dimensional solutions

Prostate cancer management: long-term beliefs, epidemic developments in the early twenty-first century and 3PM dimensional solutions

Family History of Cancers Increases Risk of Renal Cell Carcinoma in a Chinese Population

Upregulated PPARG2 facilitates interaction with demethylated AKAP12 gene promoter and suppresses proliferation in prostate cancer

Contact Info

Product

Resources

About